TY - JOUR T1 - Genomic Sequencing for Newborn Screening: Results of the NC NEXUS Project JF - medRxiv DO - 10.1101/2020.02.26.20024679 SP - 2020.02.26.20024679 AU - Tamara S. Roman AU - Stephanie B. Crowley AU - Myra I. Roche AU - Ann Katherine M. Foreman AU - Julianne M. O’Daniel AU - Bryce A. Seifert AU - Kristy Lee AU - Alicia Brandt AU - Chelsea Gustafson AU - Daniela M. DeCristo AU - Natasha T. Strande AU - Lori Ramkissoon AU - Laura V. Milko AU - Phillips Owen AU - Sayanty Roy AU - Mai Xiong AU - Ryan S. Paquin AU - Rita M. Butterfield AU - Megan A. Lewis AU - Katherine J. Souris AU - Donald B. Bailey, Jr. AU - Christine Rini AU - Jessica K. Booker AU - Bradford C. Powell AU - Karen E. Weck AU - Cynthia M. Powell AU - Jonathan S. Berg Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/29/2020.02.26.20024679.abstract N2 - Newborn screening (NBS) was established as a public health program in the 1960’s and is crucial for facilitating detection of certain medical conditions in which early intervention can prevent serious, life-threatening health problems. Genomic sequencing can potentially expand the screening for rare hereditary disorders, but many questions surround its possible use for this purpose. We examined the use of exome sequencing (ES) for NBS in the North Carolina Newborn Exome Sequencing for Universal Screening (NC NEXUS) project, comparing the yield from ES used in a screening versus a diagnostic context. We enrolled healthy newborns and children with metabolic diseases or hearing loss (106 participants total). ES confirmed the participant’s underlying diagnosis in 15 out of 17 (88%) children with metabolic disorders, and in 5 out of 28 (∼18%) children with hearing loss.We discovered actionable findings in 4 participants that would not have been detected by standard NBS. A subset of parents was eligible to receive additional information for their child about childhood-onset conditions with low or no clinical actionability, clinically actionable adult-onset conditions, and carrier status for autosomal recessive conditions. We found pathogenic variants associated with hereditary breast and/or ovarian cancer in 2 children, a likely pathogenic variant in the gene associated with Lowe syndrome in one child, and an average of 1.8 reportable variants per child for carrier results. These results highlight the benefits and limitations of using genomic sequencing for NBS and the challenges of using such technology in future precision medicine approaches.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; D.B.B. is involved in an unrelated research study that receives equipment and reagents from Asuragen; B.C.P. is an investigator on a different research study that receives in-kind support (reagents and sequencing consumables) from Illumina (San Diego, CA); K.E.W. is President and Chair of the Executive Committee and Board of Directors for the Association for Molecular Pathology, and is also a member of the Advisory Committee for the U.S. F.D.A. Medical Devices Molecular and Clinical Genetics Devices Panel and a member of the Consultant Advisory Panel for BlueCross BlueShield of North Carolina; no other relationships or activities that could appear to have influenced the submitted work.Clinical TrialNCT02826694Funding StatementThis work was funded by the National Human Genome Research Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health as part of the Newborn Sequencing in Genomic Medicine and Public Health (NSIGHT) Program, U19 HD077632.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesVariants reported in this manuscript have been submitted to the ClinVar database. http://ncbi.nlm.nih.gov/clinvar/ ER -